Merlintrader Regulatory Deep Dive · July 13, 2026

FDA U-Turns: Moderna $MRNA, Sarepta $SRPT and uniQure $QURE Lead a Year of Regulatory Reversals

Six major cases — including Regenxbio, Replimune and Valneva — show how quickly a drug review, safety restriction or approval pathway can change when new evidence, a formal appeal, patient urgency and leadership turnover collide.

$MRNA · mFlusiva $SRPT · Elevidys $QURE · AMT-130 $RGNX · NAVSUNLI $REPL · RP1 $VALN · IXCHIQ

In the space of roughly one year, the U.S. Food and Drug Administration refused to review a Moderna vaccine application and accepted a revised version eight days later; asked uniQure to run a randomized sham-controlled study and then allowed its existing Phase I/II evidence to support an accelerated-approval filing; rejected Regenxbio’s Hunter syndrome gene therapy and later said no additional patients or studies were required; and gave Replimune a rapid third review after two Complete Response Letters.

At the same time, the agency moved in the opposite direction on safety. It requested a broad suspension of Sarepta’s Elevidys distribution, reopened treatment for ambulatory patients ten days later, and subsequently imposed a boxed warning and narrowed the indication. With Valneva’s IXCHIQ, the FDA lifted a pause for older adults on August 6, 2025, only to suspend the vaccine’s U.S. license on August 22.

These cases are not identical, and calling every change an error would be misleading. Safety assessments should change when new adverse-event evidence appears. Regulatory appeals are designed to reconsider disputed decisions. Amended applications can solve technical filing problems. The controversy begins when the public record suggests that the required evidentiary standard itself moved — particularly when no new pivotal trial was completed between “insufficient” and “acceptable for filing.”

Verification status: Regulatory status, dated events and upcoming milestones were rechecked against FDA materials, SEC filings, company regulatory updates and Reuters through July 13, 2026. For RP1, Replimune says the FDA told the company to expect a late-July advisory committee meeting; as of publication, a specific meeting date had not been identified on the FDA public calendar.

The strongest evidentiary reversal

uniQure moved from an agreed external-control strategy, to a demand for a new sham-controlled trial, and back to a near-term accelerated-approval filing based primarily on the three-year Phase I/II analysis.

The broadest public-interest case

Moderna’s first seasonal mRNA flu vaccine went from a refusal-to-file decision to a full FDA review and unanimous advisory-committee support within four months.

The clearest safety counterexample

IXCHIQ shows why a reversal is not automatically regulatory inconsistency: postmarketing safety evidence can materially alter the benefit-risk balance in days.

Six major FDA reversals in one view

Company	Asset	Initial FDA position	Later position	Status on July 13, 2026
Moderna $MRNA	mFlusiva mRNA-1010	February 10, 2026: refusal to file because the comparator was judged inadequate for older adults.	February 18: amended application accepted. June 18: advisers unanimously backed a favorable benefit-risk profile for adults 50 and older.	Decision pending FDA action expected August 5, 2026.
Sarepta $SRPT	Elevidys	July 18, 2025: FDA requested suspension of all distribution amid three fatal acute-liver-failure reports across Sarepta’s AAVrh74 platform.	July 28: ambulatory distribution could resume after one death was judged unrelated to Elevidys; non-ambulatory use remained paused.	Restricted label Boxed warning; indication limited to ambulatory DMD patients.
uniQure $QURE	AMT-130	March 2026: Phase I/II plus external-control data deemed insufficient; randomized sham-controlled study strongly recommended.	June 17: three-year Phase I/II analysis deemed acceptable as the primary basis of an accelerated-approval BLA.	Filing path reopened BLA planned for Q3 2026.
Regenxbio $RGNX	NAVSUNLI RGX-121	February 7, 2026 CRL cited patient-definition, external-control and surrogate-endpoint uncertainty; possible new study and untreated control were listed.	May 14: the partial clinical hold on RGX-121 had been lifted. June 22: existing data could be considered for accelerated approval without additional patients, studies or an untreated control.	Path reopened Type A meeting expected in July; BLA resubmission targeted for Q3.
Replimune $REPL	RP1 plus nivolumab	July 2025 and April 2026 CRLs said the single-arm melanoma evidence did not provide adequate, well-controlled proof of effectiveness.	May 29: FDA agreed to an urgent resubmission. June 26: application accepted as a Class 1 response with an unusually short review clock.	High-stakes review Company-reported late-July advisory committee expected; specific FDA calendar date not yet public. Action date August 2.
Valneva $VALN	IXCHIQ	May 9, 2025: pause recommended for people 60 and older after serious adverse events.	August 6: pause lifted with stronger warnings. August 22: U.S. license suspended after further safety review.	U.S. program withdrawn Valneva withdrew the U.S. BLA and IND in January 2026.

What actually counts as an FDA “U-turn”?

The phrase is useful, but it can flatten very different regulatory events into one dramatic headline. A fair analysis separates at least four categories.

A filing reversal: the FDA initially refuses to begin a substantive review, then accepts an amended application. Moderna is the clearest example.
An evidentiary reversal: the agency changes its view on whether an existing dataset can serve as the primary basis for approval. uniQure and Regenxbio fall most clearly into this category.
A procedural or appeal-driven reopening: a rejected application returns after formal escalation, additional analyses, a revised package or intervention by senior officials. Replimune belongs here.
A safety reversal: the permitted population or market access changes as causality assessments and postmarketing reports evolve. Sarepta and Valneva illustrate how quickly this can happen.

Important distinction: an FDA agreement to accept or review an application is not an approval and does not establish that a product is safe or effective. Several companies in this report still face binary regulatory decisions.

1. Moderna: from “we will not review it” to unanimous panel support

$MRNA

Moderna’s mFlusiva case is the most accessible example because it concerns seasonal influenza rather than an ultra-rare disorder. The candidate, also known as mRNA-1010, could become the first seasonal mRNA influenza vaccine approved in the United States.

February 10, 2026: Moderna disclosed that FDA had issued a refusal-to-file letter. According to the company and Reuters, the sole cited reason was the choice of comparator: a licensed standard-dose seasonal flu vaccine rather than a comparator reflecting what the agency considered the best available standard of care for older adults.

February 11: FDA publicly defended the decision, emphasizing that adults 65 and older are commonly recommended enhanced influenza vaccines, including high-dose products.

February 18: after further discussions, the agency accepted an amended application. Moderna separated the regulatory request into traditional approval for adults 50–64 and accelerated approval for adults 65 and older, supported by a postapproval study commitment.

June 18: FDA’s Vaccines and Related Biological Products Advisory Committee unanimously concluded that mFlusiva’s benefits outweighed its risks in both age groups under review.

August 5, 2026: current FDA target date for a decision.

What changed?

The underlying Phase 3 efficacy result did not suddenly appear during the eight days between refusal and acceptance. The compromise was regulatory: a revised application structure, a different approval pathway for older adults and a commitment to generate additional evidence after approval if the older group receives accelerated approval.

That makes the case controversial in two directions. FDA’s first position can be defended on the principle that a new vaccine should be compared with the most appropriate option for the population at highest risk. Moderna’s objection is also substantial: the company said the comparator had been discussed with the agency before the trial, the letter identified no product-level safety or efficacy concern, and the pivotal program enrolled more than 40,000 adults.

Why it matters: a refusal-to-file decision is not a negative review after weighing the full evidence. It prevents the normal review from starting. When that decision is reversed in eight days, investors are left asking whether the initial obstacle was scientifically essential or procedurally solvable from the beginning.

What remains uncertain

Advisory committees are not binding. FDA can still reject, narrow or condition an approval. The older-adult pathway is particularly important because the agency has asked whether immune responses and effectiveness can be bridged adequately to a population for whom enhanced-dose vaccines are already available. Approval would validate a major non-COVID use of Moderna’s mRNA platform; a rejection would reopen the argument over trial comparators and vaccine policy.

2. Sarepta: a ten-day reversal that did not end the Elevidys safety crisis

$SRPT

Elevidys is the opposite of a simple approval-pathway dispute. It is an already marketed gene therapy for Duchenne muscular dystrophy, and the FDA’s changing actions were tied to an evolving investigation into fatal acute liver failure associated with Sarepta’s AAVrh74 platform.

June 24, 2025: FDA reported two fatal acute-liver-failure cases in non-ambulatory boys treated with Elevidys. Sarepta had already paused distribution for non-ambulatory patients.

July 18: after receiving a third fatal acute-liver-failure report involving another Sarepta AAVrh74 gene-therapy program, FDA requested that the company suspend all Elevidys distribution and placed multiple clinical trials on hold.

July 28: FDA recommended removing the voluntary hold for ambulatory patients after concluding that the death of an eight-year-old boy under investigation was unrelated to Elevidys. The non-ambulatory hold remained because of two earlier deaths.

November 14: FDA approved a boxed warning for serious liver injury and acute liver failure and revised the indication so that Elevidys was limited to ambulatory DMD patients.

Why this is a real reversal — and why it is not equivalent to uniQure

The July 18 request covered all distribution. Ten days later, ambulatory use could resume. That is a clear operational reversal, but it followed additional causality review. FDA concluded that a separate reported death in an eight-year-old boy was unrelated to Elevidys, supporting the restart for ambulatory patients, while the two fatal liver-failure cases in non-ambulatory patients continued to drive restrictions. Updating an action as the causal picture changes is what a pharmacovigilance system is supposed to do.

The later boxed warning and narrowed label also show that the July 28 reopening was not a declaration that the entire safety problem had disappeared. FDA continued to distinguish between ambulatory and non-ambulatory patients and ultimately formalized the risk in labeling.

The central risk lesson: in one-time gene therapies, a small number of severe events can radically change the addressable population, commercial outlook and required monitoring. “Distribution resumed” is not the same as “safety concern resolved.”

The unresolved controversy

Elevidys had already become one of the FDA’s most debated gene-therapy approvals because its accelerated approval and subsequent label expansion relied on a complex mix of micro-dystrophin expression, functional data and regulatory judgment. The 2025 safety crisis added another layer: how much uncertainty should be tolerated for a progressive fatal childhood disease, and how quickly should an agency act when causality is not yet fully established?

3. uniQure: the clearest change in the evidentiary goalposts

$QURE

Among the six cases, AMT-130 is the hardest to explain as a simple administrative correction. The public record documents agreement, rejection and renewed agreement over whether a small Phase I/II program compared with a natural-history external control can support an accelerated-approval filing in Huntington’s disease.

December 10, 2024, and June 2, 2025: uniQure announced FDA alignment that Phase I/II data compared with a natural-history external control could serve as the primary basis of an accelerated-approval BLA. FDA also supported cUHDRS as an intermediate clinical endpoint and agreed on a prespecified three-year comparison using ENROLL-HD external-control data.

September 24, 2025: uniQure reported that high-dose AMT-130 slowed disease progression by 75% on cUHDRS at three years versus a propensity score-matched external control (p=0.003). Total Functional Capacity, a key secondary endpoint, showed 60% slowing (p=0.033).

November 3: after a pre-BLA meeting, uniQure said FDA no longer agreed that the Phase I/II studies versus an external control might be adequate as primary evidence for a BLA.

March 2, 2026: final meeting feedback stated that the existing data were insufficient and strongly recommended a prospective, randomized, double-blind, sham-procedure-controlled study.

June 17: after a new Type B meeting, FDA communicated that the three-year Phase I/II analysis would be acceptable as the primary basis of an accelerated-approval BLA. The agency also opened the door to a confirmatory study using concurrent standard-of-care controls rather than a sham procedure.

What did not happen between March and June

No new pivotal randomized efficacy trial was completed. The change came through regulatory engagement, reconsideration of the accelerated-approval framework and a different approach to the confirmatory study. Additional analyses and follow-up can always refine a dossier, but the central three-year dataset was already public before the March demand for a new trial.

The regulatory contradiction is stark: how can an external-control dataset be acceptable, then inadequate without a new pivotal trial, and then acceptable again as the primary basis of a BLA?

Why the FDA’s caution was not irrational

Huntington’s disease progresses heterogeneously. External controls can be affected by selection bias, differences in care, missing data and imperfect matching. AMT-130 is delivered directly into the brain through a complex neurosurgical procedure, making a false-positive efficacy conclusion unusually consequential. FDA officials publicly defended the preference for a randomized controlled design as the conventional standard for proving effectiveness.

Why the reversal matters

Huntington’s disease has no approved therapy that slows progression. A sham-controlled neurosurgical study could take years and raises ethical and recruitment challenges. The new path attempts to split the difference: use the existing evidence for an accelerated-approval filing while designing a confirmatory study that may avoid sham brain procedures.

uniQure intends to submit the BLA in the third quarter of 2026. That is not a guarantee of acceptance or approval. The company still must align with FDA on the confirmatory study, chemistry and manufacturing, labeling and the totality of the benefit-risk package.

4. Regenxbio: a CRL, an appeal and a return to the original rare-disease premise

$RGNX

NAVSUNLI, previously known as RGX-121, is a one-time investigational gene therapy designed to deliver a functioning iduronate-2-sulfatase gene to the central nervous system in boys with neuronopathic MPS II, or Hunter syndrome.

May 2025: FDA accepted the BLA under the accelerated-approval pathway.

January 28, 2026: Regenxbio disclosed that FDA had placed RGX-111 and RGX-121 on clinical hold after an asymptomatic intraventricular CNS tumor was identified in a five-year-old RGX-111 participant about four years after treatment. Preliminary testing found an AAV integration event associated with PLAG1 overexpression, but causality had not been established at the time. The RGX-121 hold was precautionary because of product and population similarities; no neoplasm had been reported in the 32 RGX-121 participants.

February 7: FDA issued a CRL for RGX-121. The letter cited uncertainty over defining the neuronopathic population, comparability of the natural-history external control and whether CSF HS D2S6 was a surrogate endpoint reasonably likely to predict clinical benefit.

Potential paths listed in the CRL: a new study, additional treated patients, longer follow-up and incorporation of an untreated control arm.

May 14: Regenxbio reported that FDA had lifted the partial clinical hold on RGX-121.

June 22: following Regenxbio’s appeal, FDA acknowledged that the existing clinical data could be considered under accelerated approval and said the company would not need additional patients, new studies or the previously recommended untreated control.

The practical meaning of the reversal

Regenxbio did not receive approval. It received a path to resubmit using longer-term biomarker and clinical data already being generated in the CAMPSIITE study. The partial clinical hold on RGX-121 had already been lifted by May 14. FDA requested a Type A meeting, expected in July, and indicated that it would review the resubmission on an expedited basis.

The reversal is important because the proposed untreated-control requirement was not a small technical request. In a progressive pediatric neurodegenerative disease, untreated boys may lose abilities that cannot be recovered. Recruiting an untreated control group can therefore be ethically and practically difficult, particularly in an ultra-rare population.

What changed publicly: the June position returned much closer to the development premise on which Regenxbio had built the original application — a small treated cohort, natural-history context, biomarker evidence and longer-term clinical follow-up.

What can still derail NAVSUNLI

FDA can still conclude that the biomarker is not sufficiently predictive, that the patient population is not adequately defined, that manufacturing issues remain unresolved, or that longer-term clinical evidence does not support the proposed label. Although the partial hold on RGX-121 was lifted, the separate RGX-111 tumor investigation remains relevant to the broader safety assessment of related AAV programs.

5. Replimune: two CRLs, political attention and an unusually fast third review

$REPL

Replimune’s RP1 is an oncolytic immunotherapy being reviewed in combination with nivolumab for advanced melanoma that progressed after anti-PD-1 therapy. The regulatory dispute centers on whether the single-arm IGNYTE study can provide substantial evidence of effectiveness for accelerated approval.

July 21, 2025: FDA issued the first CRL. The agency said the single-arm trial was not an adequate and well-controlled investigation and that heterogeneity in the patient population made the results difficult to interpret against historical controls.

October 20: FDA accepted a resubmission containing additional information, data and analyses, with an April 10, 2026 action date.

April 10, 2026: FDA issued a second CRL, again concluding that the application lacked adequate evidence from a well-controlled trial. Replimune shares fell 58% in extended trading, according to Reuters.

May 5: then-Commissioner Marty Makary publicly defended the rejection, saying the company had not run the control group the agency had recommended.

May 29: Replimune announced agreement on another resubmission, with FDA indicating it would treat the filing as an urgent matter because of the unmet need in advanced melanoma.

June 26: FDA accepted the application as a complete Class 1 response and assigned an August 2 action date. Replimune said the agency told the company to expect an advisory committee meeting in late July; as of July 13, a specific date had not been identified on FDA’s public advisory-committee calendar.

Why the case is politically sensitive

Reuters and The Wall Street Journal reported that Replimune engaged the White House after the second rejection and that administration officials asked health authorities to reconsider the process. The available reporting does not establish that the White House ordered FDA to approve RP1. It does, however, make the rapid reopening impossible to analyze as a purely private sponsor-agency discussion.

Has the evidentiary problem disappeared?

No. Acceptance of the resubmission means FDA considers the response complete enough to review; it does not erase the two CRLs. If the expected advisory committee is convened, outside experts will confront the same central question: can a response-rate and durability signal from a heterogeneous single-arm trial be interpreted reliably enough to support accelerated approval in a population with limited options?

Binary catalyst: RP1 now has the nearest decisive event in this group. A company-reported late-July advisory committee, if formally scheduled, and the August 2 action date could either validate the reopened path or show that rapid reconsideration did not resolve the underlying evidentiary dispute.

6. Valneva: the reversal that moved from caution to reopening — and then to suspension

$VALN

IXCHIQ is a live attenuated chikungunya vaccine originally approved in the United States through the accelerated-approval pathway in November 2023. Its 2025 sequence is the strongest reminder that not all FDA reversals are philosophical changes. Some are driven by fast-moving pharmacovigilance evidence.

May 9, 2025: FDA and CDC recommended pausing use in people 60 and older while investigating serious neurologic and cardiac events.

August 6: FDA lifted the pause, revised the indication and added stronger limitations, warnings and precautions, particularly for older adults with chronic medical conditions.

August 22: CBER suspended the biologics license. FDA cited chikungunya-like illness in vaccine recipients, more than 20 serious adverse events, 21 hospitalizations and three deaths, including one encephalitis death directly attributable to the vaccine strain.

January 19, 2026: Valneva voluntarily withdrew the U.S. BLA and IND after the license suspension and a further clinical hold.

Why the August reversal was so abrupt

The FDA safety communication said the benefit-risk analysis no longer showed benefits outweighing risks under most plausible scenarios and noted that clinical benefit had not yet been verified in confirmatory studies. The product contained a live weakened virus, and the reported adverse events resembled severe chikungunya illness itself.

Only sixteen days separated the lifting of the older-adult pause from suspension of the entire U.S. license. That timing looks chaotic from the outside. It is also consistent with a regulator responding to additional cases, revised causal attribution and an updated benefit-risk model.

Why IXCHIQ matters to the broader comparison: it prevents the simplistic conclusion that every FDA reversal reflects political interference or inconsistent standards. Sometimes the safety evidence genuinely changes — and when it does, market access can disappear faster than it returned.

The common pattern: in several cases, the FDA changed what evidence it was willing to consider

The six cases reveal three overlapping stories.

1. Rare-disease flexibility returned after a period of stricter control demands

uniQure and Regenxbio both faced demands that moved toward randomized or untreated controls after earlier FDA interactions had supported external-control strategies. By June 2026, both companies had regained paths based primarily on existing clinical programs, with confirmatory obligations shifted or redesigned.

This does not prove that the earlier reviewers were wrong or that the newer position is correct. It does show that “regulatory flexibility” is not an abstract phrase. It determines whether a company must spend years running another trial, whether patients can access a therapy through accelerated approval, and whether a small biotech can finance the remaining development.

2. Leadership, escalation and formal appeals can change the path without a new pivotal trial

Several reversals followed formal appeals, meetings with senior officials, public disputes or leadership turnover. Replimune’s third review followed White House attention and senior changes at FDA. Regenxbio explicitly obtained its new path through an appeal. uniQure’s position changed after renewed Type B engagement. Moderna publicly challenged its refusal-to-file letter before an amended application was accepted.

It would be irresponsible to claim that politics dictated the scientific conclusions. The narrower, supportable conclusion is that decision-making authority, review philosophy and escalation channels were part of the sequence and may have materially influenced the regulatory path.

3. The stock market prices the FDA’s interpretation, not just the clinical data

uniQure lost more than a third of its value after the March demand for another study and surged more than 75% when the filing path reopened. Replimune fell 58% after its second CRL and rose 86% after the urgent resubmission agreement. Regenxbio dropped after the CRL and gained when the additional-study requirement was removed. Moderna’s refusal-to-file letter moved not only its own shares but broader vaccine-sector sentiment.

These moves were not reactions to conventional Phase 3 readouts. They were reactions to changes in how FDA would interpret or process evidence already generated.

For biotech investors, regulatory consistency is not a side issue. It is part of the asset’s valuation, financing risk and probability of approval.

How investors should read the next controversial FDA reversal

The wrong response is to assume that every reversal makes approval inevitable. The better approach is to identify exactly which layer changed.

Signals that a reversal may be substantive

FDA explicitly removes a previously required new trial or control arm.
The agency agrees that an existing dataset may serve as the primary basis of a BLA.
A formal appeal results in written alignment on the approval pathway.
A Class 1 resubmission receives a short statutory review clock.
Label discussions, confirmatory-study design and manufacturing review move forward in parallel.

Signals that the headline may overstate the change

The FDA merely accepts a filing without changing its efficacy concerns.
The update comes only from a company press release before meeting minutes are finalized.
A review is reopened but the original CRL deficiencies remain unresolved.
The path depends on a future advisory committee or postapproval trial that may be difficult to execute.
A safety hold is lifted for one subgroup while warnings or restrictions intensify elsewhere.

Read the verbs carefully

In FDA reporting, the difference between accepted for review, agreed the data may support a filing, recommended approval and approved is enormous. Sponsors naturally emphasize the most constructive interpretation. Primary documents, Complete Response Letters, FDA safety communications, SEC filings and advisory-committee materials should take priority over promotional summaries.

Separate accelerated approval from traditional approval

Several cases in this report involve accelerated approval, which can permit earlier market access based on an intermediate or surrogate endpoint reasonably likely to predict clinical benefit. That flexibility comes with confirmatory-study obligations and the risk of withdrawal if benefit is not verified. A reopened accelerated-approval path does not mean the FDA has concluded that definitive clinical benefit is already proven.

Do not ignore financing risk

A reversal can rescue an asset while leaving the balance sheet damaged by the months of uncertainty. Companies may have cut staff, delayed manufacturing, raised capital at depressed prices or restructured programs after a CRL. The regulatory headline should therefore be analyzed alongside cash runway, dilution, commercial readiness and the cost of required confirmatory trials.

Next catalysts and decision points

Expected timing	Company / asset	Event	What to watch
Late July 2026	Replimune / RP1	Company-reported expected FDA advisory committee; specific public date not yet posted as of July 13	Whether a meeting is formally scheduled and, if held, whether external experts believe the IGNYTE single-arm evidence and durability support accelerated approval despite two prior CRLs.
August 2, 2026	Replimune / RP1	FDA action date	Approval, another CRL, restricted indication or additional postmarketing requirements.
August 5, 2026	Moderna / mFlusiva	FDA action date	Traditional approval for ages 50–64, accelerated approval for 65+, labeling and postapproval commitments.
July–Q3 2026	Regenxbio / NAVSUNLI	Type A meeting and BLA resubmission	Final agreement on biomarker, longer-term clinical package, label population, safety and expedited review timing.
Q3 2026	uniQure / AMT-130	Planned BLA submission	Confirmatory-study design, control strategy, acceptance of the BLA and any CMC issues.
Ongoing	Sarepta / Elevidys	Post-marketing safety monitoring	Additional liver-safety events, compliance with revised labeling, ambulatory benefit-risk evidence and any further regulatory action.
No active U.S. filing	Valneva / IXCHIQ	U.S. BLA and IND withdrawn	International pharmacovigilance, regulatory decisions outside the U.S. and whether a future U.S. path is ever rebuilt.

Bull case, bear case and the bigger biotech read-through

The constructive interpretation

The FDA may be restoring pragmatic flexibility for serious and ultra-rare diseases after a period in which conventional control requirements threatened to make development impractical. Appeals and senior review are functioning as intended. Accelerated approval can allow earlier access while confirmatory studies continue. For small biotech, this could reopen investment in external controls, natural-history datasets, biomarkers and small-population gene-therapy programs.

The cautious interpretation

Rapid swings can undermine confidence that pre-trial FDA agreements will survive leadership changes. If standards depend heavily on who controls a review division, companies cannot reliably design studies or forecast capital needs. More permissive filings could also lead to approvals based on uncertain evidence, followed by difficult confirmatory trials, safety restrictions or withdrawals.

The strongest conclusion supported by the evidence

The FDA has not abandoned science, and the public record does not justify a blanket allegation that its decisions were politically dictated. It does justify concern about predictability. In multiple high-profile cases, the acceptable evidentiary path changed after public conflict, appeal or leadership turnover — sometimes without a newly completed pivotal trial.

That distinction matters. Regulatory flexibility is necessary when diseases are rare, progressive or fatal. But flexibility that cannot be anticipated becomes regulatory volatility. Patients may welcome a reopened path, while developers and investors still need to know whether today’s agreement will remain valid when the application reaches a different review team.

Bottom line

Moderna, Sarepta and uniQure provide the most recognizable headlines, but the broader pattern becomes visible only when Regenxbio, Replimune and Valneva are added.

Moderna shows how a filing objection can be restructured in days. Sarepta shows how a broad safety action can be narrowed after causality review while the underlying risk remains serious. uniQure shows the clearest swing in what evidence the FDA would accept. Regenxbio shows the power of a formal appeal in an ultra-rare pediatric disease. Replimune shows how political visibility and leadership turnover can surround a reopened review without resolving the clinical debate. Valneva shows that new safety evidence can justify a reversal in the opposite direction.

The next test arrives quickly. Replimune and Moderna face August decisions, while uniQure and Regenxbio prepare new filings. Those outcomes will reveal whether the recent reversals represent a durable FDA philosophy — or another temporary phase in an agency whose interpretation of evidence has become one of biotech’s most powerful and least predictable catalysts.

Primary documents and reporting

Company releases describe the sponsors’ understanding of FDA interactions and may precede final agency meeting minutes. A company statement that FDA expects an advisory committee does not substitute for a meeting date published on FDA’s calendar. Where available, this report prioritizes FDA documents, public Complete Response Letters, SEC filings and major wire reporting.

Real-Time Market Scanner

Professional Trading Workflow